CETIRIZINE HYDROCHLORIDE ALLERGY Drug Patent Profile
✉ Email this page to a colleague
When do Cetirizine Hydrochloride Allergy patents expire, and what generic alternatives are available?
Cetirizine Hydrochloride Allergy is a drug marketed by Apotex, Aurobindo Pharma Ltd, Bionpharma, Catalent, Strides Pharma, Sun Pharm Inds Inc, Perrigo R And D, Amneal Pharms Ny, Apotex Inc, Cipla Ltd, Contract Pharmacal, Dr Reddys Labs Ltd, Glenmark Pharms Inc, Granules, Heritage Pharma, Ipca Labs Ltd, Marksans Pharma, Mylan, Orbion Pharms, Pld Acquisitions, Sun Pharm Inds Ltd, Taro, Torrent Pharms Llc, Unichem, and Unique. and is included in twenty-eight NDAs.
The generic ingredient in CETIRIZINE HYDROCHLORIDE ALLERGY is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and fifty-five suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cetirizine Hydrochloride Allergy
A generic version of CETIRIZINE HYDROCHLORIDE ALLERGY was approved as cetirizine hydrochloride by TEVA PHARMS on May 27th, 2008.
Summary for CETIRIZINE HYDROCHLORIDE ALLERGY
US Patents: | 0 |
Applicants: | 25 |
NDAs: | 28 |
Finished Product Suppliers / Packagers: | 132 |
Raw Ingredient (Bulk) Api Vendors: | 119 |
Clinical Trials: | 88 |
Patent Applications: | 2,859 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CETIRIZINE HYDROCHLORIDE ALLERGY at DailyMed |
Recent Clinical Trials for CETIRIZINE HYDROCHLORIDE ALLERGY
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
State University of New York - Upstate Medical University | Phase 3 |
Ultragenyx Pharmaceutical Inc | Phase 1/Phase 2 |
Emory University | Phase 4 |
Pharmacology for CETIRIZINE HYDROCHLORIDE ALLERGY
Drug Class | Histamine-1 Receptor Antagonist |
Mechanism of Action | Histamine H1 Receptor Antagonists |